Table 1.

Outcomes and Baseline Characteristics Among Patients With COVID-19 Stratified Into Those With Preexisting Liver Disease and Without Liver Disease

	Before propensity matching			After propensity matching
	COVID-19 with liver disease (n = 250)	COVID-19 without liver disease (n = 2530)	RR, RD, or P value	COVID-19 with liver disease (n = 250)	COVID-19 without liver disease (n = 250)	RR, RD, or P value
Outcomes
Mortality, %, (n/total)	12.0 (30/250)	4.3 (110/2530)	RR: 2.8 (1.9, 4.0) RD: 7.7% (3.5%, 11.75%) P < .001	12.0 (30/250)	4.0 (10/250)	RR: 3.0 (1.5, 6.0) RD: 8.0% (3.3%, 12.7%) P = .001
Hospitalization rate	52.0 (130/250)	30.0 (760/2530)	RR: 1.7 (1.2, 2.0) RD: 22.0% (15.5%, 28.4%) P < .001	48.0 (120/250)	36.0 (90/250)	RR: 1.3 (1.1, 1.6) RD: 12.0% (3.4%, 20.6%) P = .006
Characteristics
Age, y, mean ± SD	55.2 ± 14.6	51.6 ± 17.8	<.01	55.4 ± 14.4	56.7 ± 15.3	.36
Female, n (%)	140 (56)	1570 (62)	.06	140 (56)	140 (56)	1.00
Race: white, n (%)	130 (52)	1220 (48.2)	.25	130 (52)	130 (52)	1.00
Nicotine dependence, n (%)	60 (24)	190 (7.5)	<.01	50 (20)	50 (20)	1.00
Body mass index >30.0 to 30.9 kg/m2, n (%)	60 (24)	310 (12.5)	<.01	50 (20)	50 (20)	1.00
Race: black or African American, n (%)	100 (40)	1000 (39.5)	.88	100 (40)	110 (44)	.36
Hypertension, n (%)	170 (68)	1020 (40.3)	<.01	170 (68)	170 (68)	1.00
Diabetes mellitus, n (%)	120 (48)	520 (14.8)	<.01	110 (44)	110 (44)	1.00
Chronic lower respiratory diseases, n (%)	100 (40)	280 (11.0)	<.01	100 (40)	70 (28)	.01
Chronic kidney disease, n (%)	80 (32)	305 (7.2)	<.01	80 (32)	50 (20)	.01
Heart failure, n (%)	60 (24)	220 (8.7)	<.01	60 (24)	50 (20)	.28

NOTE. Outcomes and baseline characteristics are compared before and after propensity score matching of groups.

RD, risk difference; RR, risk ratio; SD, standard deviation.